<?xml version="1.0" encoding="utf-8"?>
<export-example>
  <doc>
    <id>1294</id>
    <completedYear>2019</completedYear>
    <publishedYear/>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst/>
    <pageLast/>
    <pageNumber/>
    <edition/>
    <issue>11</issue>
    <volume>9</volume>
    <type>article</type>
    <publisherName>MDPI</publisherName>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>1</belongsToBibliography>
    <completedDate>--</completedDate>
    <publishedDate>2019-10-30</publishedDate>
    <thesisDateAccepted>--</thesisDateAccepted>
    <title language="eng">Synergy of Chemo- and Photodynamic Therapies with C60 Fullerene-Doxorubicin Nanocomplex</title>
    <abstract language="eng">A nanosized drug complex was explored to improve the efficiency of cancer chemotherapy, complementing it with nanodelivery and photodynamic therapy. For this, nanomolar amounts of a non-covalent nanocomplex of Doxorubicin (Dox) with carbon nanoparticle C60 fullerene (C60) were applied in 1:1 and 2:1 molar ratio, exploiting C60 both as a drug-carrier and as a photosensitizer. The fluorescence microscopy analysis of human leukemic CCRF-CEM cells, in vitro cancer model, treated with nanocomplexes showed Dox’s nuclear and C60’s extranuclear localization. It gave an opportunity to realize a double hit strategy against cancer cells based on Dox’s antiproliferative activity and C60’s photoinduced pro-oxidant activity. When cells were treated with 2:1 C60-Dox and irradiated at 405 nm the high cytotoxicity of photo-irradiated C60-Dox enabled a nanomolar concentration of Dox and C60 to efficiently kill cancer cells in vitro. The high pro-oxidant and pro-apoptotic efficiency decreased IC50 16, 9 and 7 × 103-fold, if compared with the action of Dox, non-irradiated nanocomplex, and C60’s photodynamic effect, correspondingly. Hereafter, a strong synergy of therapy arising from the combination of C60-mediated Dox delivery and C60 photoexcitation was revealed. Our data indicate that a combination of chemo- and photodynamic therapies with C60-Dox nanoformulation provides a promising synergetic approach for cancer treatment.</abstract>
    <parentTitle language="eng">Nanomaterials</parentTitle>
    <identifier type="issn">2079-4991</identifier>
    <identifier type="urn">urn:nbn:de:kobv:526-opus4-12940</identifier>
    <enrichment key="opus.import.user">sword</enrichment>
    <enrichment key="opus.import.date">2019-12-13T01:52:58+00:00</enrichment>
    <enrichment key="opus.import.file">attachment; filename=deposit.zip</enrichment>
    <enrichment key="opus.import.checksum">f988bbe021d54d197e59d010cfa1917a</enrichment>
    <enrichment key="SourceTitle">Grebinyk, A., Prylutska, S., Chepurna, O., Grebinyk, S., Prylutskyy, Y., Ritter, U., et al. (2019). Synergy of Chemo- and Photodynamic Therapies with C60 Fullerene-Doxorubicin Nanocomplex Nanomaterials. 9 (11), 1540.</enrichment>
    <enrichment key="DOI_VoR">https://doi.org/10.3390/nano9111540</enrichment>
    <licence>Creative Commons - CC BY - Namensnennung 4.0 International</licence>
    <author>Anna Grebinyk</author>
    <author>Svitlana Prylutska</author>
    <author>Oksana Chepurna</author>
    <author>Sergii Grebinyk</author>
    <author>Yuriy Prylutskyy</author>
    <author>Uwe Ritter</author>
    <author>Tymish Y. Ohulchanskyy</author>
    <author>Olga Matyshevska</author>
    <author>Thomas Dandekar</author>
    <author>Marcus Frohme</author>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>photodynamic chemotherapy</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>synergistic effect</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>C60 fullerene</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>doxorubicin</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>nanocomplex</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>leukemic cell</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>apoptosis</value>
    </subject>
    <collection role="ddc" number="570">Biowissenschaften; Biologie</collection>
    <collection role="institutes" number="">Fachbereich Ingenieur- und Naturwissenschaften</collection>
    <collection role="open_access" number="">open_access</collection>
    <collection role="Import" number="import">Import</collection>
    <collection role="Funding" number="">DFG-geförderter Publikationsfonds</collection>
    <collection role="green_open_access" number="1">Gold Open Access</collection>
    <thesisPublisher>Technische Hochschule Wildau</thesisPublisher>
    <file>https://opus4.kobv.de/opus4-th-wildau/files/1294/nanomaterials-09-01540.pdf</file>
  </doc>
  <doc>
    <id>1096</id>
    <completedYear>2019</completedYear>
    <publishedYear/>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst/>
    <pageLast/>
    <pageNumber/>
    <edition/>
    <issue/>
    <volume>14</volume>
    <type>article</type>
    <publisherName/>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>1</belongsToBibliography>
    <completedDate>--</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>--</thesisDateAccepted>
    <title language="eng">Complexation with C60 Fullerene Increases Doxorubicin Efficiency against Leukemic Cells In Vitro</title>
    <abstract language="eng">Conventional anticancer chemotherapy is limited because of severe side effects as well as a quickly evolving multidrug resistance of the tumor cells. To address this problem, we have explored a C60 fullerene-based nanosized system as a carrier for anticancer drugs for an optimized drug delivery to leukemic cells.&#13;
&#13;
Here, we studied the physicochemical properties and anticancer activity of C60 fullerene noncovalent complexes with the commonly used anticancer drug doxorubicin. C60-Doxorubicin complexes in a ratio 1:1 and 2:1 were characterized with UV/Vis spectrometry, dynamic light scattering, and high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). The obtained analytical data indicated that the 140-nm complexes were stable and could be used for biological applications. In leukemic cell lines (CCRF-CEM, Jurkat, THP1 and Molt-16), the nanocomplexes revealed ≤ 3.5 higher cytotoxic potential in comparison with the free drug in a range of nanomolar concentrations. Also, the intracellular drug’s level evidenced C60 fullerene considerable nanocarrier function.&#13;
&#13;
The results of this study indicated that C60 fullerene-based delivery nanocomplexes had a potential value for optimization of doxorubicin efficiency against leukemic cells.</abstract>
    <parentTitle language="eng">Nanoscale Research Letters</parentTitle>
    <identifier type="issn">1556-276X</identifier>
    <identifier type="urn">urn:nbn:de:kobv:526-opus4-10966</identifier>
    <note>Das Dokument wurde zurückgezogen. Die korrigierte Version ist unter dem folgenden Link zu finden: https://nbn-resolving.org/urn:nbn:de:kobv:526-opus4-11415</note>
    <enrichment key="SourceTitle">Grebinyk, A., Prylutska, S., Grebinyk, S. et al. Nanoscale Res Lett (2019) 14: 61. https://doi.org/10.1186/s11671-019-2894-1</enrichment>
    <enrichment key="RelatedIdentifier">https://nbn-resolving.org/urn:nbn:de:kobv:526-opus4-11415</enrichment>
    <licence>Creative Commons - CC BY - Namensnennung 4.0 International</licence>
    <author>Anna Grebinyk</author>
    <author>Svitlana Prylutska</author>
    <author>Sergii Grebinyk</author>
    <author>Yuriy Prylutskyy</author>
    <author>Uwe Ritter</author>
    <author>Olga Matyshevska</author>
    <author>Thomas Dandekar</author>
    <author>Marcus Frohme</author>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>C60 fullerene</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>doxorubicin</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>noncovalent complex</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>leukemic cell</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>cytotoxicity</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>accumulation</value>
    </subject>
    <collection role="ddc" number="570">Biowissenschaften; Biologie</collection>
    <collection role="institutes" number="">Fachbereich Ingenieur- und Naturwissenschaften</collection>
    <collection role="green_open_access" number="1">Gold Open Access</collection>
    <thesisPublisher>Technische Hochschule Wildau</thesisPublisher>
  </doc>
  <doc>
    <id>1141</id>
    <completedYear>2019</completedYear>
    <publishedYear/>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst/>
    <pageLast/>
    <pageNumber/>
    <edition/>
    <issue/>
    <volume>14</volume>
    <type>article</type>
    <publisherName/>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>1</belongsToBibliography>
    <completedDate>--</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>--</thesisDateAccepted>
    <title language="eng">Complexation with C60 Fullerene Increases Doxorubicin Efficiency against Leukemic Cells In Vitro</title>
    <abstract language="eng">Conventional anticancer chemotherapy is limited because of severe side effects as well as a quickly evolving multidrug resistance of the tumor cells. To address this problem, we have explored a C60 fullerene-based nanosized system as a carrier for anticancer drugs for an optimized drug delivery to leukemic cells.&#13;
&#13;
Here, we studied the physicochemical properties and anticancer activity of C60 fullerene noncovalent complexes with the commonly used anticancer drug doxorubicin. C60-Doxorubicin complexes in a ratio 1:1 and 2:1 were characterized with UV/Vis spectrometry, dynamic light scattering, and high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). The obtained analytical data indicated that the 140-nm complexes were stable and could be used for biological applications. In leukemic cell lines (CCRF-CEM, Jurkat, THP1 and Molt-16), the nanocomplexes revealed ≤ 3.5 higher cytotoxic potential in comparison with the free drug in a range of nanomolar concentrations. Also, the intracellular drug’s level evidenced C60 fullerene considerable nanocarrier function.&#13;
&#13;
The results of this study indicated that C60 fullerene-based delivery nanocomplexes had a potential value for optimization of doxorubicin efficiency against leukemic cells.</abstract>
    <parentTitle language="eng">Nanoscale Research Letters</parentTitle>
    <identifier type="issn">1556-276X</identifier>
    <identifier type="urn">urn:nbn:de:kobv:526-opus4-11415</identifier>
    <enrichment key="SourceTitle">Grebinyk, A., Prylutska, S., Grebinyk, S. et al. Nanoscale Res Lett (2019) 14: 61. https://doi.org/10.1186/s11671-019-2894-1</enrichment>
    <enrichment key="DOI_VoR">https://doi.org/10.1186/s11671-019-2894-1</enrichment>
    <licence>Creative Commons - CC BY - Namensnennung 4.0 International</licence>
    <author>Anna Grebinyk</author>
    <author>Svitlana Prylutska</author>
    <author>Sergii Grebinyk</author>
    <author>Yuriy Prylutskyy</author>
    <author>Uwe Ritter</author>
    <author>Olga Matyshevska</author>
    <author>Thomas Dandekar</author>
    <author>Marcus Frohme</author>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>C60 fullerene</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>doxorubicin</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>noncovalent complex</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>leukemic cell</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>cytotoxicity</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>accumulation</value>
    </subject>
    <collection role="ddc" number="570">Biowissenschaften; Biologie</collection>
    <collection role="institutes" number="">Fachbereich Ingenieur- und Naturwissenschaften</collection>
    <collection role="open_access" number="">open_access</collection>
    <collection role="Funding" number="">DFG-geförderter Publikationsfonds</collection>
    <collection role="green_open_access" number="1">Gold Open Access</collection>
    <thesisPublisher>Technische Hochschule Wildau</thesisPublisher>
    <file>https://opus4.kobv.de/opus4-th-wildau/files/1141/2019_NRL_Grebinyk.pdf</file>
  </doc>
  <doc>
    <id>1036</id>
    <completedYear>2018</completedYear>
    <publishedYear/>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst>2047</pageFirst>
    <pageLast>2052</pageLast>
    <pageNumber/>
    <edition/>
    <issue/>
    <volume>19</volume>
    <type>article</type>
    <publisherName/>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>1</belongsToBibliography>
    <completedDate>--</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>--</thesisDateAccepted>
    <title language="eng">HPLC-ESI-MS method for C60 fullerene mitochondrial content quantification</title>
    <abstract language="eng">The presented dataset describes the quantification of carbon nanoparticle C60 fullerene accumulated in mitochondria of human leukemic cells treated with nanostructure. Firstly, the high performance liquid chromatography–electro spray ionization–mass spectrometry (HPLC-ESI-MS) method was developed for quantitative analysis of pristine C60 fullerene. Then, human leukemic cells were incubated with C60 fullerene, homogenized and subjected to the differential centrifugation to retrieve mitochondrial fraction. The C60 fullerene content was quantified by HPLC-ESI-MS in extracts of cellular fractions.&#13;
&#13;
This data article refers to the research article “C60 Fullerene Accumulation in Human Leukemic Cells and Perspectives of LED-mediated Photodynamic Therapy” by Grebinyk et al.</abstract>
    <parentTitle language="eng">Data in Brief</parentTitle>
    <identifier type="issn">2352-3409</identifier>
    <identifier type="urn">urn:nbn:de:kobv:526-opus4-10368</identifier>
    <enrichment key="SourceTitle">Grebinyk, A., Grebinyk, S., Prylutska, S., Ritter, U., Matyshevska, O., Dandekar, T., et al. (2018). HPLC-ESI-MS method for C60 fullerene mitochondrial content quantification Data in Brief. 19, 2047-2052. https://doi.org/10.1016/j.dib.2018.06.089</enrichment>
    <enrichment key="DOI_VoR">https://doi.org/10.1016/j.dib.2018.06.089</enrichment>
    <licence>Creative Commons - CC BY - Namensnennung 4.0 International</licence>
    <author>Anna Grebinyk</author>
    <author>Sergii Grebinyk</author>
    <author>Svitlana Prylutska</author>
    <author>Uwe Ritter</author>
    <author>Olga Matyshevska</author>
    <author>Thomas Dandekar</author>
    <author>Marcus Frohme</author>
    <collection role="ddc" number="570">Biowissenschaften; Biologie</collection>
    <collection role="institutes" number="">Fachbereich Ingenieur- und Naturwissenschaften</collection>
    <collection role="open_access" number="">open_access</collection>
    <collection role="Funding" number="">DFG-geförderter Publikationsfonds</collection>
    <collection role="green_open_access" number="1">Gold Open Access</collection>
    <thesisPublisher>Technische Hochschule Wildau</thesisPublisher>
    <file>https://opus4.kobv.de/opus4-th-wildau/files/1036/1-s2.0-S2352340918307406-main.pdf</file>
  </doc>
  <doc>
    <id>1058</id>
    <completedYear>2018</completedYear>
    <publishedYear/>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst>319</pageFirst>
    <pageLast>327</pageLast>
    <pageNumber/>
    <edition/>
    <issue/>
    <volume>124</volume>
    <type>article</type>
    <publisherName/>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>1</belongsToBibliography>
    <completedDate>--</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>--</thesisDateAccepted>
    <title language="eng">C60 fullerene accumulation in human leukemic cells and perspectives of LED-mediated photodynamic therapy</title>
    <abstract language="eng">Recent progress in nanobiotechnology has attracted interest to a biomedical application of the carbon nanostructure C60 fullerene since it possesses a unique structure and versatile biological activity. C60 fullerene potential application in the frame of cancer photodynamic therapy (PDT) relies on rapid development of new light sources as well as on better understanding of the fullerene interaction with cells.&#13;
&#13;
The aim of this study was to analyze C60 fullerene effects on human leukemic cells (CCRF-CEM) in combination with high power single chip light-emitting diodes (LEDs) light irradiation of different wavelengths: ultraviolet (UV, 365 nm), violet (405 nm), green (515 nm) and red (632 nm). The time-dependent accumulation of fullerene C60 in CCRF-CEM cells up to 250 ng/106 cells at 24 h with predominant localization within mitochondria was demonstrated with immunocytochemical staining and liquid chromatography mass spectrometry. In a cell viability assay we studied photoexcitation of the accumulated C60 nanostructures with ultraviolet or violet LEDs and could prove that significant phototoxic effects did arise. A less pronounced C60 fullerene phototoxic effect was observed after irradiation with green, and no effect was detected with red light. A C60 fullerene photoactivation with violet light induced substantial ROS generation and apoptotic cell death, confirmed by caspase3/7 activation and plasma membrane phosphatidylserine externalization. Our work proved C60 fullerene ability to induce apoptosis of leukemic cells after photoexcitation with high power single chip 405 nm LED as a light source. This underlined the potential for application of C60 nanostructure as a photosensitizer for anticancer therapy.</abstract>
    <parentTitle language="eng">Free Radical Biology and Medicine</parentTitle>
    <identifier type="issn">1873-4596</identifier>
    <identifier type="urn">urn:nbn:de:kobv:526-opus4-10588</identifier>
    <enrichment key="SourceTitle">Grebinyk, A. et al. (2018). C60 fullerene accumulation in human leukemic cells and perspectives of LED-mediated photodynamic therapy Free Radical Biology and Medicine. 124, 319-327.</enrichment>
    <enrichment key="DOI_VoR">https://doi.org/10.1016/j.freeradbiomed.2018.06.022</enrichment>
    <licence>Creative Commons - CC BY - Namensnennung 4.0 International</licence>
    <author>Anna Grebinyk</author>
    <author>Sergii Grebinyk</author>
    <author>Svitlana Prylutska</author>
    <author>Uwe Ritter</author>
    <author>Olga Matyshevska</author>
    <author>Thomas Dandekar</author>
    <author>Marcus Frohme</author>
    <collection role="ddc" number="570">Biowissenschaften; Biologie</collection>
    <collection role="institutes" number="">Fachbereich Ingenieur- und Naturwissenschaften</collection>
    <collection role="open_access" number="">open_access</collection>
    <collection role="green_open_access" number="4">Hybrid Open Access</collection>
    <thesisPublisher>Technische Hochschule Wildau</thesisPublisher>
    <file>https://opus4.kobv.de/opus4-th-wildau/files/1058/1-s2.0-S0891584918311043-main.pdf</file>
  </doc>
  <doc>
    <id>1477</id>
    <completedYear>2019</completedYear>
    <publishedYear/>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst/>
    <pageLast/>
    <pageNumber/>
    <edition/>
    <issue/>
    <volume/>
    <type>conferenceobject</type>
    <publisherName/>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>1</belongsToBibliography>
    <completedDate>--</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>--</thesisDateAccepted>
    <title language="eng">LED-based portable light source for photodynamic therapy</title>
    <abstract language="eng">Photodynamic therapy (PDT) employs light activation of tissue-localized photosensitizer in an oxygen-dependent process which initiates oxidative stress, inflammation, and cell death. Laser systems, which are mostly used in PDT as light sources can be costly and oversized. light-emitting diodes (LEDs) equipment has a high potential to simplify technical part of phototriggered therapies and to reduce its costs. We develop the LED-based system that includes the control and irradiation units. The system provides the same power density at any irradiation point. Among the advantages of the device is a possibility to change the irradiation area and tune the irradiation dose. PDT experiments with cancer cells in vitro treated with two different photosensitizers demonstrated a possibility to use the developed LED-based system as a low-cost light source in PDT.</abstract>
    <identifier type="urn">urn:nbn:de:kobv:526-opus4-14778</identifier>
    <enrichment key="opus.import.date">2021-08-26T11:19:53+00:00</enrichment>
    <enrichment key="opus.source">sword</enrichment>
    <enrichment key="opus.import.user">sword</enrichment>
    <enrichment key="opus.import.file">filename=phpCgvAlh</enrichment>
    <enrichment key="opus.import.checksum">c2d415e2348cf5f248f3ea95b8aac99c</enrichment>
    <enrichment key="DOI_VoR">https://doi.org/10.1117/12.2541774</enrichment>
    <enrichment key="SourceTitle">O. Chepurna, A. Grebinyk, Yu. Petrushko, S. Prylutska, S. Grebinyk, V. M. Yashchuk, O. Matyshevska, U. Ritter, T. Dandekar, M. Frohme, J. Qu, and T. Y. Ohulchanskyy, "LED-based portable light source for photodynamic therapy", Proc. SPIE 11190, Optics in Health Care and Biomedical Optics IX, 111901A (20 November 2019); https://doi.org/10.1117/12.2541774</enrichment>
    <enrichment key="CopyrightInfo">Copyright 2019 Society of Photo-Optical Instrumentation Engineers (SPIE). One print or electronic copy may be made for personal use only. Systematic reproduction and distribution, duplication of any material in this paper for a fee or for commercial purposes, or modification of the content of the paper are prohibited.</enrichment>
    <licence>Das Dokument ist urheberrechtlich geschützt.</licence>
    <author>Oksana Chepurna</author>
    <author>Anna Grebinyk</author>
    <author>Yulia Petrushko</author>
    <author>Svitlana Prylutska</author>
    <author>Sergii Grebinyk</author>
    <author>Valeriy Yashchuk</author>
    <author>Olga Matyshevska</author>
    <author>Uwe Ritter</author>
    <author>Thomas Dandekar</author>
    <author>Marcus Frohme</author>
    <author>Junle Qu</author>
    <author>Tymish Y. Ohulchanskyy</author>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>light source</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>high power single chip LED</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>photodynamic therapy</value>
    </subject>
    <collection role="ddc" number="621">Angewandte Physik</collection>
    <collection role="institutes" number="">Fachbereich Ingenieur- und Naturwissenschaften</collection>
    <collection role="open_access" number="">open_access</collection>
    <collection role="Import" number="import">Import</collection>
    <collection role="green_open_access" number="2">Green Open Access</collection>
    <thesisPublisher>Technische Hochschule Wildau</thesisPublisher>
    <file>https://opus4.kobv.de/opus4-th-wildau/files/1477/111901A.pdf</file>
  </doc>
  <doc>
    <id>1293</id>
    <completedYear>2019</completedYear>
    <publishedYear/>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst/>
    <pageLast/>
    <pageNumber/>
    <edition/>
    <issue>11</issue>
    <volume>11</volume>
    <type>article</type>
    <publisherName>MDPI</publisherName>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>1</belongsToBibliography>
    <completedDate>--</completedDate>
    <publishedDate>2019-11-08</publishedDate>
    <thesisDateAccepted>--</thesisDateAccepted>
    <title language="eng">C60 Fullerene as an Effective Nanoplatform of Alkaloid Berberine Delivery into Leukemic Cells</title>
    <abstract language="eng">A herbal alkaloid Berberine (Ber), used for centuries in Ayurvedic, Chinese, Middle-Eastern, and native American folk medicines, is nowadays proved to function as a safe anticancer agent. Yet, its poor water solubility, stability, and bioavailability hinder clinical application. In this study, we have explored a nanosized carbon nanoparticle—C60 fullerene (C60)—for optimized Ber delivery into leukemic cells. Water dispersions of noncovalent C60-Ber nanocomplexes in the 1:2, 1:1, and 2:1 molar ratios were prepared. UV–Vis spectroscopy, dynamic light scattering (DLS), and atomic force microscopy (AFM) evidenced a complexation of the Ber cation with the negatively charged C60 molecule. The computer simulation showed that π-stacking dominates in Ber and C60 binding in an aqueous solution. Complexation with C60 was found to promote Ber intracellular uptake. By increasing C60 concentration, the C60-Ber nanocomplexes exhibited higher antiproliferative potential towards CCRF-CEM cells, in accordance with the following order: free Ber &lt; 1:2 &lt; 1:1 &lt; 2:1 (the most toxic). The activation of caspase 3/7 and accumulation in the sub-G1 phase of CCRF-CEM cells treated with C60-Ber nanocomplexes evidenced apoptosis induction. Thus, this study indicates that the fast and easy noncovalent complexation of alkaloid Ber with C60 improved its in vitro efficiency against cancer cells.</abstract>
    <parentTitle language="eng">Pharmaceutics</parentTitle>
    <identifier type="issn">1999-4923</identifier>
    <identifier type="urn">urn:nbn:de:kobv:526-opus4-12932</identifier>
    <enrichment key="opus.import.user">sword</enrichment>
    <enrichment key="opus.import.date">2019-12-12T23:05:01+00:00</enrichment>
    <enrichment key="opus.import.file">attachment; filename=deposit.zip</enrichment>
    <enrichment key="opus.import.checksum">d3b76ebd17631c1dd7d3f3f0bd6f6ea4</enrichment>
    <enrichment key="SourceTitle">Grebinyk, A., Prylutska, S., Buchelnikov, A., Tverdokhleb, N., Grebinyk, S., Evstigneev, M., et al. (2019). C60 Fullerene as an Effective Nanoplatform of Alkaloid Berberine Delivery into Leukemic Cells Pharmaceutics. 11 (11), 586.</enrichment>
    <enrichment key="DOI_VoR">https://doi.org/10.3390/pharmaceutics11110586</enrichment>
    <licence>Creative Commons - CC BY - Namensnennung 4.0 International</licence>
    <author>Anna Grebinyk</author>
    <author>Svitlana Prylutska</author>
    <author>Anatoliy Buchelnikov</author>
    <author>Nina Tverdokhleb</author>
    <author>Sergii Grebinyk</author>
    <author>Maxim Evstigneev</author>
    <author>Olga Matyshevska</author>
    <author>Vsevolod Cherepanov</author>
    <author>Yuriy Prylutskyy</author>
    <author>Valeriy Yashchuk</author>
    <author>Anton Naumovets</author>
    <author>Uwe Ritter</author>
    <author>Thomas Dandekar</author>
    <author>Marcus Frohme</author>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>C60 fullerene</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>berberine</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>noncovalent nanocomplex</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>UV–Vis</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>DLS and AFM measurements</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>drug release</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>leukemic cell</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>uptake</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>cytotoxicity</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>apoptosis</value>
    </subject>
    <collection role="ddc" number="570">Biowissenschaften; Biologie</collection>
    <collection role="institutes" number="">Fachbereich Ingenieur- und Naturwissenschaften</collection>
    <collection role="open_access" number="">open_access</collection>
    <collection role="Import" number="import">Import</collection>
    <collection role="Funding" number="">DFG-geförderter Publikationsfonds</collection>
    <collection role="green_open_access" number="1">Gold Open Access</collection>
    <thesisPublisher>Technische Hochschule Wildau</thesisPublisher>
    <file>https://opus4.kobv.de/opus4-th-wildau/files/1293/pharmaceutics-11-00586-v2.pdf</file>
  </doc>
</export-example>
